FORM PTO-1449

INFORMATION DISCLOSURE

ATTORNEY DOCKET NO.: F7649(V)

SERIAL NO.: 10/519.657

FILING DATE: December 22, 2004

STATEMENT BY APPLICANT					CONFIRMATION NO.: 9203			Page 1 of 1
			U.S. PA	TENT DOCU	JMENTS			
EXAMINER INITIALS		DOCUMENT NO.	DATE	NAME OF	INVENTOR	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	1	5,821,217	10/13/98	Forse et al		514	2	
	2	2002/0019334	02/14/02	Portman		514	2	
	3	2002/037830	03/28/02	Berthelsen	et al.	514	2	
	4	2005/0238694	10/27/05	Gerhardt e	t al.	424	439	
			FOREIGN	PATENT DO	CUMENTS			
EXAMINER INITIALS		DOCUMENT NO.	DATE	COUNTRY		CLASS	SUBCLASS	TRANSLATION YES OR NO
	5	629 350	12/21/94	Europe				
	6	1 112 693	07/04/01	Europe				
	7	01/85984	11/15/01	PCT				
	8	2004/002241	01/08/04	PCT				
	9	2 489 942	01/08/04	Canada				
			отн	ER DOCUME	NTS			
	12	Drucker, "Development of Glucagon-Like Peptide-1-Based Pharmaceuticals as Therapeutic Agents for the Treatment of Diabetes", Current Pharmaceutical Design, 2001, 7, pgs. 1399-1412.						
	11	function in type 2 diabetes: a parallel-group study, the Lancet Vol. 359, 3/902, pp. 324-453. Toft-Nielsen, "Determinants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes", J. Clinical Endocrinol Metab 2001, 8/86(8): 3853-60.						
	12							
	13							
	14 Harper, "Biological Properties of Whey Components A Review", The American Dairy Products Institute, 2001, pg							2001, pgs. 1-20
	15							
	16							
	17							
	18	Co-pending Application: Attorney Docket No.: F7	Applicant: Ger 683(V)	hardt et al., S	erial No. 10/539,	434; Filed: Januar	y 13, 2006;	
XAMINER	/.leff	rey Russel/	(•/			NSIDERED	03/24/20	00

IINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THORUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.